MétaCan
Menu
← Back to cohort
Record W4402495356 · doi:10.1016/j.ijrobp.2024.09.002

The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial

2024· article· en· W4402495356 on OpenAlexaff
Rachel Glicksman, Srinivas Raman, Xiang Y. Ye, Philippe L. Bédard, Scott V. Bratman, Eric X. Chen, Peter Chung, Laura A. Dawson, Andrew Hope, Ali Hosni, Joanna Javor, Patricia Lindsay, Ciara O’Brien, Rebecca Wong, Aisling Barry, Joelle Helou

Bibliographic record

VenueInternational Journal of Radiation Oncology*Biology*Physics · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsWestern UniversityUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsRandomized controlled trialMedicineRadiation therapyPhase (matter)OncologyInternal medicinePhysics

Abstract

fetched live from OpenAlex

PURPOSE: In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changing systemic therapy (ST), stereotactic body radiation therapy (SBRT) is being explored as an alternative local therapy targeting the sites of progression. METHODS AND MATERIALS: RADIANT (NCT04122469) was a single-center phase 2 study of patients with metastatic genitourinary (GU), breast, and gastrointestinal (GI) cancers, receiving ST for ≥3 months, with radiographic OP disease in ≤5 sites. Patients received SBRT for all OP disease in 1 to 5 fractions and were maintained on ST. The primary endpoint was the cumulative incidence of change in ST, which was estimated using the Aalen-Johansen method. Secondary endpoints included progression-free survival (PFS) and overall survival estimated using the Kaplan-Meier method, as well as toxicity and health-related quality of life. Comparisons between diagnosis groups were done using the log-rank test. A 2-sided p value <.05 was considered statistically significant. RESULTS: Seventy patients were analyzed, with a median age of 69 years; 32 patients (46%) were women; the median number of lines of prior ST was 3. Primary sites were GU (n = 32; 46%), breast (n = 23; 33%), and GI (n = 15; 21%). The median follow-up was 12.3 months (IQR, 8.2-21.6 months). At 1 year, change in ST occurred in 47% (95% CI, 36%-61%) (GU 45%, breast 41%, and GI 60%; p = .23). PFS at 1 year was 32% (95% CI, 23%-45%), and median PFS was 4.7 months (95% CI, 3.8-8.1) (GU 4.8, breast 6.5, and GI 3.2), which significantly differed by disease type (p = .006). Overall survival was 75% at 1 year (95% CI, 65%-87%), which significantly differed between cancer types (GU 86%, breast 96%, and GI 22%; p < .001). The cumulative incidence of late grade ≥2 toxicity was 1.2%, with 1 patient experiencing late grade 3 toxicity and no grade 4 to 5 acute or late toxicities. Health-related quality of life declined from the mean (SD) of 66.9 (20.2) at baseline to 60.5 (22.2) at 6 months, which did not meet the threshold for a minimal clinically important difference. CONCLUSIONS: SBRT for OP metastases delayed change in ST in approximately half of patients, warranting investigation in randomized trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.339
Teacher spread0.329 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2024
Admission routes1
Has abstractno

Explore more

Same venueInternational Journal of Radiation Oncology*Biology*Physics→Same topicBreast Cancer Treatment Studies→French-language works237,207→